Introduction
The pan-European survey of hospital pharmacy practice conducted by the European Association of Hospital Pharmacists (EAHP) is an important source of information for understanding future professional challenges and system development needs in Europe. The methodology and the background of the 2010 survey were previously described in this journal. 1 In this article we present the production and quality assurance findings.
Results
In general, the number of hospital pharmacies across Europe producing medicines for stock and for individual prescriptions has decreased substantially since 2000 (figure 1). 2 This is especially the case for the production of stock sterile medicines, which the 2010 survey shows to be less than half of that recorded in the 2000 survey (decreasing from 66.8% to 29.9% of pharmacies). However, the 2010 survey also recorded a 32% decrease (from 71.0% to 48.5% of pharmacies) since 2000 in pharmacy involvement in the production of individual sterile preparations. Production for all preparations is highly dependent on the size of the hospital (table 1) with the larger units recording significantly more production activity.
While reagents for laboratories are seldom produced in hospital pharmacies (16.5% of pharmacies), production of nonsterile medicines is common, especially for individual prescriptions (65.8 of pharmacies). Across Europe, only 43.8% of pharmacies reconstitute cytotoxics: this practice occurs in around 80% of large hospitals but in <20% of small hospitals (as they may not need this service). Centralisation of admixtures is still quite low (max. 8.5% of pharmacies for all units and 23.5% for special units) but in contrast compounding of total parenteral nutrition (TPN) seems to be well developed (64.7% of the very large hospitals).This is not surprising considering the high costs of the facilities needed in particular for the aseptic production.
As regards determining the costeffectiveness of production, 77.5% of pharmacies record the costs of the raw materials (n=920) and 42.7% labour costs, while only 23.7% take into consideration equipment depreciation and 28.4% quality control costs. Regulations across Europe in relation to hospital pharmacy production differ and a licence to supply own products to other hospitals is not mandatory in all countries. Only 18.5% of pharmacies supply other hospitals (n=999) and 41% of these do so in order to generate hospital revenue (n=159).
There are also some differences between eastern and western Europe, particularly as regards licences for in-house production and manufacture for other hospitals and outpatients (table 2) .
In The number of hospital pharmacies in Europe producing sterile as well as non-sterile medicines has decreased significantly since 2000. In addition, the number of pharmacies preparing total parenteral nutrition, cytotoxics and intravenous admixtures (24.6%, 43.8% and 8.0% of pharmacies, respectively) is quite low and depends to a large extent on the size of the pharmacies, with larger units generally demonstrating significantly higher production activity. There are some differences between eastern and western Europe. Quality control and good manufacturing practice (GMP) seem to be well implemented (61.3% of pharmacies have adopted GMP) and many pharmacies have external certification.
licensed pharmacies. Only oncology hospitals are involved in advanced therapy (6.3%).
Quality of production is high as 61.3% of pharmacies reported that GMP has been implemented (n=949) and 64.4% have a written procedure for the recall of their own products (n=964). However, the situation differs by country (figure 2). For example, there is quite a gap between some countries (Denmark, Finland, Sweden and UK) and eastern Baltic countries, where only a few hospitals have implemented GMP, possibly because of economic constraints.
Awareness of quality control and assurance is also demonstrated by the high number of hospital pharmacies who have achieved certification (figure 3). Due to the existence of other implemented certification systems, in some countries such as France and Belgium ISO certification is group.bmj.com on December 10, 2012 -Published by ejhp.bmj.com Downloaded from not the most commonly used accreditation standard, and, at least in Belgium, some pharmacies have two certificates (which explains the total percentage being >100%). There are large differences across Europe with some countries (Estonia, Ireland and Luxembourg) having no certification according to our data.
The survey suggests that the presence of quality control systems is highly dependent on the size of the hospital in question (table 3, n=986) , with large hospitals more commonly having such systems. The quality control of chemical and physical elements is generally less robust than that of microbiological stability. Raw materials and finished products are well tested (67.3% and 67.9% of pharmacies, respectively) with packaging material less so (22.3%). In general the tests are performed in the pharmacy (67.3% of pharmacies) but also at external locations (67.9%) or in other laboratories of the same hospital (22.3%).
Limitations
In addition to some of the previously discussed and accepted limitations of the EAHP survey, 1 since 2005 a number of eastern countries with low hospital pharmacy production and quality control have joined EAHP. This may have created a bias by increasing the true decline in such activities. Also the results concerning GMP are surprising and should be treated with caution; it is possible that some respondents may have misinterpreted the term 'GMP' (which means fulfilling the EU directive) as meaning a more general 'best practice'.
Discussion
The decrease in the numbers of hospital pharmacies involved in sterile batch production could be due to increased group.bmj.com on December 10, 2012 -Published by ejhp.bmj.com Downloaded from reliance on industrial manufacture, as well as the concentration of production in larger hospital pharmacies. There are similar decreases in production activity in relation to individual preparations, at least for small and medium-sized hospitals. This development is regrettable in light of the needs of personalised medicine and the fact that only pharmacists are competent within hospitals to create such preparations. Nevertheless, the EAHP survey did not seek information about the outsourcing of production, which might have been relevant in terms of the results. It is also surprising that only 43.8% of the pharmacies surveyed offered centralised cytotoxic reconstitution. Even though only some hospitals are involved in oncology, this percentage is low with only 53.1% of oncology hospitals offering such a service (data not shown). We were unable to determine from the survey results whether this is the result of outsourcing or of reconstitution in the ward, both of which practices contravene the recommendations of the International Pharmaceutical Federation (FIP) Basel statements of 2008. 3 Also the preparation of intravenous admixtures needs to be improved as they can be very sensitive microbiologically and should therefore be prepared in the pharmacy as suggested in Basel statement 36. 3 The low percentage of hospital pharmacies meeting this standard (max 23.5%) is therefore unsatisfactory.
Our data show that hospital pharmacies are not yet ready to prepare advanced medicines. This is not yet an acute need but may be so in the future. As regards personalised medicines, preparation competencies within hospital pharmacies should be maintained.
Hospital pharmacies in Europe in general show a good understanding of quality control and assurance and have often achieved external certification. Nevertheless, the need to meet GMP requirements in the future may challenge some small pharmacies and the trends towards concentration in larger production facilities-as suggested by our results from 2000 and 2005-will probably continue.
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